These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 22481232)

  • 41. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
    Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
    Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
    Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
    Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy.
    Ouyang WW; Su SF; Ma Z; Hu YX; Lu B; Li QS; Geng YC; Li HQ
    Radiat Oncol; 2014 Jun; 9():147. PubMed ID: 24962716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
    Movsas B; Langer CJ; Ross HJ; Wang L; Jotte RM; Feigenberg S; Xu F; Huang CH; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2010 May; 5(5):673-9. PubMed ID: 20354453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
    Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
    J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
    Zou B; Xu Y; Li T; Li W; Tang B; Zhou L; Li L; Liu Y; Zhu J; Huang M; Wang J; Ren L; Gong Y; Che G; Liu L; Hou M; Lu Y
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):321-8. PubMed ID: 19775829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
    Yan D; Wei P; An G; Chen W
    J Cardiothorac Surg; 2013 Jun; 8():149. PubMed ID: 23759026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
    Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
    World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
    Dudek AZ; Lesniewski-Kmak K; Larson T; Dragnev K; Isaksson R; Gupta V; Maddaus MA; Kratzke RA
    J Thorac Oncol; 2009 Aug; 4(8):969-75. PubMed ID: 19633472
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
    Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C
    J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
    Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
    Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
    Scagliotti GV; Ricardi U; Crinó L; Maranzano E; De Marinis F; Morandi MG; Meacci L; Marangolo M; Emiliani E; Rosti G; Figoli F; Bolzicco G; Masiero P; Gentile A; Tonato M
    Cancer Chemother Pharmacol; 1996; 38(6):561-5. PubMed ID: 8823499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
    Donington J; Hu X; Zhang S; Song Y; Arunachalam A; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    Clin Lung Cancer; 2024 Jul; 25(5):440-448. PubMed ID: 38627155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
    Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
    Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A
    J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
    Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
    Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
    Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1005-1024. PubMed ID: 38319500
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
    Granetzny A; Striehn E; Bosse U; Wagner W; Koch O; Vogt U; Froeschle P; Klinke F
    Zentralbl Chir; 2003 Aug; 128(8):640-4. PubMed ID: 12931258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.